Skip to content

GSK Drops Regulatory Plan for Arthritis Drug as Tests Disappoint

GSK Plc won’t submit an experimental rheumatoid arthritis therapy to regulators after disappointing clinical trial results. 

One study for the medicine, a monoclonal antibody called otilimab, failed to meet its goal. While another two did succeed, GSK said Thursday that “the efficacy demonstrated is unlikely to transform patient care.”